Scholarlink

Background <p>This study aimed to assess the safety and efficacy of virtual reality (VR) visual stimulation on neuroprotection and neuroenhancement in optic neuropathy patients.</p> Methods <p>Open-label, prospective, phase I clinical trial, enrolling 21 participants with glaucoma, plus 1 patient with ischemic optic neuropathy after hydrocephalus. Participants received commercially available VR headsets (HTC Vive or Oculus Rift) for home use loaded with a study-specific visual stimulus program. The VR visual stimulation protocol consisted of up to 1-hour daily sessions, 5 days per week, for 12-week cycles repeatable for up to 24 months. Safety was assessed through adverse event monitoring, and compliance was assessed through self-report. Testing of function (visual acuity and visual field) and structure (optical coherence tomography (OCT) for retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thickness) were measured at baseline and follow-up.</p> Results <p>VR-based visual stimulation was safe and well tolerated across the 22-patient cohort. Mean baseline intraocular pressure (IOP) was 12.06 ± 0.76 mmHg and there was no significant change in IOP at follow-up. 8 of 22 patients were sufficiently compliant with use to analyze for efficacy measures. Analysis of Humphrey visual field (HVF) mean deviation (MD) of individual patients revealed that two eyes of two patients showed improvement and seven eyes of five patients showed worsening during the study duration. One patient using Goldmann visual fields (GVF) demonstrated improvement in sensitivity in both eyes. There were no statistically significant changes in visual acuity, HVF MD, GCC thickness, or RNFL thickness across the full patient population. Two illustrative cases were selected to demonstrate the potential therapeutic effects of VR visual stimulation.</p> Conclusion <p>These findings demonstrate that VR-based visual stimulation is safe, well-tolerated, and may provide functional benefits in selected patients. Additional studies are warranted to further investigate this therapeutic approach.</p> Trial registration <p>ClinicalTrials.gov, TRN: NCT07071129, Registration date: 9 July 2025, retrospectively registered.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Virtual reality stimulation for neuroprotection and neuroenhancement of vision in optic neuropathy patients: a prospective clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月20日

查看全文
  • Katherine J. Healzer,
  • Tasneem Z. Khatib,
  • Gala Beykin,
  • Zachary Wennberg-Smith,
  • Mariana Nuñez,
  • Andrew D. Huberman,
  • Jeffrey L. Goldberg

摘要

Background

This study aimed to assess the safety and efficacy of virtual reality (VR) visual stimulation on neuroprotection and neuroenhancement in optic neuropathy patients.

Methods

Open-label, prospective, phase I clinical trial, enrolling 21 participants with glaucoma, plus 1 patient with ischemic optic neuropathy after hydrocephalus. Participants received commercially available VR headsets (HTC Vive or Oculus Rift) for home use loaded with a study-specific visual stimulus program. The VR visual stimulation protocol consisted of up to 1-hour daily sessions, 5 days per week, for 12-week cycles repeatable for up to 24 months. Safety was assessed through adverse event monitoring, and compliance was assessed through self-report. Testing of function (visual acuity and visual field) and structure (optical coherence tomography (OCT) for retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thickness) were measured at baseline and follow-up.

Results

VR-based visual stimulation was safe and well tolerated across the 22-patient cohort. Mean baseline intraocular pressure (IOP) was 12.06 ± 0.76 mmHg and there was no significant change in IOP at follow-up. 8 of 22 patients were sufficiently compliant with use to analyze for efficacy measures. Analysis of Humphrey visual field (HVF) mean deviation (MD) of individual patients revealed that two eyes of two patients showed improvement and seven eyes of five patients showed worsening during the study duration. One patient using Goldmann visual fields (GVF) demonstrated improvement in sensitivity in both eyes. There were no statistically significant changes in visual acuity, HVF MD, GCC thickness, or RNFL thickness across the full patient population. Two illustrative cases were selected to demonstrate the potential therapeutic effects of VR visual stimulation.

Conclusion

These findings demonstrate that VR-based visual stimulation is safe, well-tolerated, and may provide functional benefits in selected patients. Additional studies are warranted to further investigate this therapeutic approach.

Trial registration

ClinicalTrials.gov, TRN: NCT07071129, Registration date: 9 July 2025, retrospectively registered.